Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15741
Abstract: Hedgehog pathway inhibitors (HPI) inactivating SMO 1 , have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3 . Nevertheless, common adverse events lead… read more here.
Keywords: vismodegib resistant; discontinuation; locally advanced; resistant mutations ... See more keywords